The FDA will participate in the COVID-19 Diagnostics Evidence Accelerator, a multi-stakeholder collaborative project to advance the development of diagnostics.
Daxor's BVA-100 has been used in over 45,000 patient clinical assessments and featured in over 100 published research studies, trials and case studies.